Evidence map›Paper›PMID 26940368›Full record

ArticleClinical pharmacology and therapeutics2016

Pilot PET Study to Assess the Functional Interplay Between ABCB1 and ABCG2 at the Human Blood-Brain Barrier.

M Bauer, K Römermann, R Karch, B Wulkersdorfer, J Stanek, C Philippe, A Maier-Salamon, H Haslacher, C Jungbauer, W Wadsak and 5 more

Open access · hybridAbstract read
In one paragraph

Article in Clinical pharmacology and therapeutics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
5.2field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 58 citations in OpenAlex.

  1. Trial
  2. Article
  3. Imaging the Activity of Efflux Transporters at the Blood-Brain Barrier in Neurologic Diseases: Radiotracer Selection Criteria.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025
    Review
  4. A cryopreserved andNAM journal · 2025
    Article
  5. Article
  6. In vivo methods for imaging blood-brain barrier function and dysfunction.European journal of nuclear medicine and molecular imaging · 2023
    Review
  7. Article
  8. Review
  9. Article
  10. Complete inhibition of ABCB1 and ABCG2 at the blood-brain barrier by co-infusion of erlotinib and tariquidar to improve brain delivery of the model ABCB1/ABCG2 substrate [Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2021
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Age dependency of cerebral P-glycoprotein function in wild-type and APPPS1 mice measured with PET.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2020
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 5 institutions in 2 countries.

M BauerDepartment of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria.
K RömermannDepartment of Pharmacology, Toxicology & Pharmacy, University of Veterinary Medicine, Hannover, Germany.
R KarchCenter for Medical Statistics, Informatics and Intelligent Systems, Medical University of Vienna, Vienna, Austria.
B WulkersdorferDepartment of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria.
J StanekDepartment of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria.
C PhilippeDepartment of Biomedical Imaging und Image-guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Vienna, Austria.
A Maier-SalamonDepartment of Clinical Pharmacy and Diagnostics, University of Vienna, Vienna, Austria.
H HaslacherDepartment of Laboratory Medicine, Medical University of Vienna, Vienna, Austria.
C JungbauerAustrian Red Cross Blood Transfusion Services, Vienna, Austria.
W WadsakDepartment of Biomedical Imaging und Image-guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Vienna, Austria.
W JägerDepartment of Clinical Pharmacy and Diagnostics, University of Vienna, Vienna, Austria.
W LöscherDepartment of Pharmacology, Toxicology & Pharmacy, University of Veterinary Medicine, Hannover, Germany.
M HackerDepartment of Biomedical Imaging und Image-guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Vienna, Austria.
M ZeitlingerDepartment of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria.
O LangerDepartment of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria.
Medical University of Vienna · ATUniversity of Veterinary Medicine Hannover, Foundation · DEUniversity of Vienna · ATAustrian Institute of Technology · ATAustrian Red Cross · AT

Funding

Austrian Science Fund FWF F 3513Austrian Science Fund FWF KLI 480
6 · The paper itself

Abstract

ABCB1 and ABCG2 work together at the blood-brain barrier (BBB) to limit brain distribution of dual ABCB1/ABCG2 substrates. In this pilot study we used positron emission tomography (PET) to assess brain distribution of two model ABCB1/ABCG2 substrates ([(11) C]elacridar and [(11) C]tariquidar) in healthy subjects without (c.421CC) or with (c.421CA) the ABCG2 single-nucleotide polymorphism (SNP) c.421C>A. Subjects underwent PET scans under conditions when ABCB1 and ABCG2 were functional and during ABCB1 inhibition with high-dose tariquidar. In contrast to the ABCB1-selective substrate (R)-[(11) C]verapamil, [(11) C]elacridar and [(11) C]tariquidar showed only moderate increases in brain distribution during ABCB1 inhibition. This provides evidence for a functional interplay between ABCB1 and ABCG2 at the human BBB and suggests that both ABCB1 and ABCG2 need to be inhibited to achieve substantial increases in brain distribution of dual ABCB1/ABCG2 substrates. During ABCB1 inhibition c.421CA subjects had significantly higher increases in [(11) C]tariquidar brain distribution than c.421CC subjects, pointing to impaired cerebral ABCG2 function.

Indexed as

AcridinesAdultATP Binding Cassette Transporter, Subfamily BATP Binding Cassette Transporter, Subfamily G, Member 2Blood-Brain BarrierBrainFemaleHumansMaleNeoplasm ProteinsPilot ProjectsPolymorphism, Single NucleotidePositron-Emission TomographyQuinolinesTetrahydroisoquinolinesTissue DistributionABCB1 protein, humanABCG2 protein, humanAcridinesATP Binding Cassette Transporter, Subfamily BATP Binding Cassette Transporter, Subfamily G, Member 2ElacridarNeoplasm ProteinsQuinolinestariquidarTetrahydroisoquinolinesVerapamil

Identifiers

PMID26940368
PMCPMC4979595
OpenAlexW2289139901

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.